

# Lance C W Turtle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2767416/publications.pdf>

Version: 2024-02-01

85  
papers

7,425  
citations

101543

36  
h-index

71685

76  
g-index

108  
all docs

108  
docs citations

108  
times ranked

15529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. <i>Pediatric Research</i> , 2023, 93, 207-216.	2.3	10
2	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe, The</i> , 2022, 3, e21-e31.	7.3	131
3	Mouse models of Japanese encephalitis virus infection: A systematic review and meta-analysis using a meta-regression approach. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010116.	3.0	8
4	Flavivirus cross-reactivity would explain the apparent findings of Japanese encephalitis virus infection in Nigeria. <i>Journal of Immunoassay and Immunochemistry</i> , 2022, , 1-3.	1.1	0
5	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, , ASN.2021121587.	6.1	4
6	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	27.8	174
7	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	12.8	20
8	A systematic review of brain imaging findings in neurological infection with Japanese encephalitis virus compared with Dengue virus. <i>International Journal of Infectious Diseases</i> , 2022, 119, 102-110.	3.3	7
9	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , 2022, 77, 606-615.	5.6	24
10	Methods of SARS-CoV-2 Inactivation. <i>Methods in Molecular Biology</i> , 2022, 2452, 465-473.	0.9	1
11	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. <i>Scientific Reports</i> , 2022, 12, 6843.	3.3	12
12	Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer. <i>JAMA Network Open</i> , 2022, 5, e2210880.	5.9	50
13	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac179.	0.9	10
14	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. <i>Clinical and Experimental Immunology</i> , 2022, 209, 90-98.	2.6	5
15	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
16	Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. <i>GigaScience</i> , 2022, 11, .	6.4	8
17	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2095-e2106.	5.8	218
18	Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort. <i>Leukemia and Lymphoma</i> , 2021, 62, 1682-1691.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Guillain-Barré syndrome during the Zika virus outbreak in Northeast Brazil: An observational cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117272.	0.6	24
20	Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. <i>BMJ Open</i> , 2021, 11, e048317.	1.9	1
21	What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. <i>BMJ Open</i> , 2021, 11, e043887.	1.9	51
22	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	12.8	54
23	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	161
24	Circulating histones play a central role in COVID-19-associated coagulopathy and mortality. <i>Haematologica</i> , 2021, 106, 2493-2498.	3.5	27
25	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	12.8	102
26	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 349-359.	10.7	161
27	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. <i>EBioMedicine</i> , 2021, 68, 103398.	6.1	8
28	Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples. <i>Journal of Infectious Diseases</i> , 2021, 224, 1305-1315.	4.0	38
29	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 773-785.	10.7	78
30	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , 2021, 398, 223-237.	13.7	110
31	Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK. <i>BMC Infectious Diseases</i> , 2021, 21, 784.	2.9	11
32	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	12.8	150
33	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , 2021, 2, e354-e365.	7.3	216
34	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. <i>Lancet Regional Health - Europe</i> , 2021, 8, 100186.	5.6	191
35	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. <i>Lancet</i> , 2021, 398, 1037-1038.	13.7	75
36	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	12.6	124

#	ARTICLE	IF	CITATIONS
37	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021, 591, 92-98.	27.8	1,014
38	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	28.9	262
39	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e055435.	1.9	10
40	The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. <i>iScience</i> , 2021, 24, 103353.	4.1	57
41	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. <i>Global Health Action</i> , 2021, 14, 2008139.	1.9	5
42	Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. <i>EBioMedicine</i> , 2020, 62, 103078.	6.1	16
43	Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays. <i>Journal of Infectious Diseases</i> , 2020, 222, 1462-1467.	4.0	201
44	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	14.5	1,066
45	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. <i>BMJ</i> , 2020, 370, m3249.	6.0	478
46	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. <i>Lancet Neurology</i> , 2020, 19, 826-839.	10.2	68
47	Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration. <i>ESMO Open</i> , 2020, 5, e000825.	4.5	6
48	T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 6779-6789.	3.6	13
49	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , 2020, 20, 770-772.	9.1	40
50	Respiratory failure alone does not suggest central nervous system invasion by SARS-CoV-2. <i>Journal of Medical Virology</i> , 2020, 92, 705-706.	5.0	35
51	Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. <i>Frontiers in Immunology</i> , 2020, 11, 517.	4.8	31
52	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	1.8	179
53	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	1.8	81
54	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	1.8	122

#	ARTICLE	IF	CITATIONS
55	Adenovirus Type 7 causing severe lower respiratory tract infection in immunocompetent adults: a comparison of two contrasting cases from an intensive care unit in North West England. <i>Clinical Infection in Practice</i> , 2019, 2, 100007.	0.5	2
56	“More than devastating” patient experiences and neurological sequelae of Japanese encephalitis. <i>Journal of Travel Medicine</i> , 2019, 26, .	3.0	18
57	Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007269.	3.0	14
58	Structural Study of the C-Terminal Domain of Nonstructural Protein 1 from Japanese Encephalitis Virus. <i>Journal of Virology</i> , 2018, 92, .	3.4	24
59	Risk assessment for Japanese encephalitis vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 213-217.	3.3	10
60	Japanese encephalitis – the prospects for new treatments. <i>Nature Reviews Neurology</i> , 2018, 14, 298-313.	10.1	194
61	The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	2
62	Closing The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	0
63	The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006212.	3.0	87
64	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	3.4	148
65	Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. <i>Frontiers in Immunology</i> , 2017, 8, 1309.	4.8	77
66	Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005263.	3.0	41
67	Human T cell responses to Japanese encephalitis virus in health and disease. <i>Journal of Experimental Medicine</i> , 2016, 213, 1331-1352.	8.5	96
68	An integrated model of care for neurological infections: the first six years of referrals to a specialist service at a university teaching hospital in Northwest England. <i>BMC Infectious Diseases</i> , 2015, 15, 387.	2.9	2
69	A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in Nepal. <i>PLoS ONE</i> , 2015, 10, e0122608.	2.5	39
70	A Survey of UK Healthcare Workers’ Attitudes on Volunteering to Help with the Ebola Outbreak in West Africa. <i>PLoS ONE</i> , 2015, 10, e0120013.	2.5	18
71	What stops healthcare workers volunteering to fight Ebola in west Africa?. <i>BMJ</i> , The, 2014, 349, g6443-g6443.	6.0	3
72	A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. <i>Aids</i> , 2014, 28, 2636-2637.	2.2	19

#	ARTICLE	IF	CITATIONS
73	Japanese encephalitis virus infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 561-576.	1.8	55
74	Innate Immune Mechanisms in Japanese Encephalitis Virus Infection: Effect on Transcription of Pattern Recognition Receptors in Mouse Neuronal Cells and Brain Tissue. Viral Immunology, 2013, 26, 366-377.	1.3	24
75	Japanese Encephalitis Virus Infection. , 2013, , 271-293.		0
76	Encephalitis caused by flaviviruses. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 219-223.	0.5	71
77	In routine UK hospital practice T-SPOT.TB <sup>®</sup> is useful in some patients with a modest pre-test probability of active tuberculosis. European Journal of Internal Medicine, 2012, 23, 363-367.	2.2	6
78	'Septrin psychosis' among renal transplant patients with Pneumocystis jirovecii pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 1117-1119.	3.0	10
79	An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis. Journal of Neurology, 2009, 256, 2052-2060.	3.6	44
80	Severe pneumonia caused by ciprofloxacin resistant panton-valentine leukocidin producing community acquired meticillin resistant Staphylococcus aureus. Journal of Infection, 2009, 58, 86-87.	3.3	3
81	Tics, twitches, tales: The experiences of Gilles de la Tourette's syndrome.. American Journal of Orthopsychiatry, 2008, 78, 449-455.	1.5	16
82	Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium insensitive phospholipase A 2 gene expression. FASEB Journal, 2003, 17, 2313-2315.	0.5	49
83	Comparative evaluation of ten lateral flow immunoassays to detect SARS-CoV-2 antibodies. Wellcome Open Research, 0, 6, 18.	1.8	1
84	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial. SSRN Electronic Journal, 0, , .	0.4	51
85	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. SSRN Electronic Journal, 0, , .	0.4	56